Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | 14.6x - 16.1x | 15.4x |
| Selected Fwd P/E Multiple | 7.4x - 8.2x | 7.8x |
| Fair Value | kr46.28 - kr51.15 | kr48.71 |
| Upside | 27.0% - 40.4% | 33.7% |
| Benchmarks | - | Full Ticker |
| Novo Nordisk A/S | - | CPSE:NOVOB |
| Novartis AG | - | SWX:NOVN |
| Orion Oyj | - | HLSE:ORNAV |
| AstraZeneca PLC | - | OM:AZN |
| Pfizer Inc. | - | DB:PFE |
| H. Lundbeck A/S | - | CPSE:HLUNB |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| NOVO B | NOVN | ORNAV | AZN | PFE | HLUN B | |||
| CPSE:NOVOB | SWX:NOVN | HLSE:ORNAV | OM:AZN | DB:PFE | CPSE:HLUNB | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 21.0% | 10.8% | 10.5% | 39.4% | -5.6% | 6.3% | ||
| 3Y CAGR | 28.4% | -19.5% | 19.4% | 297.5% | -29.0% | 33.6% | ||
| Latest Twelve Months | 17.2% | 41.2% | 60.2% | 22.8% | 2831.6% | 36.1% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 33.8% | 26.9% | 20.7% | 9.2% | 20.6% | 10.7% | ||
| Prior Fiscal Year | 36.0% | 18.4% | 18.2% | 13.0% | 3.6% | 11.5% | ||
| Latest Fiscal Year | 34.8% | 23.1% | 21.4% | 13.0% | 12.6% | 14.3% | ||
| Latest Twelve Months | 34.5% | 24.2% | 21.9% | 14.1% | 12.6% | 14.3% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 13.4x | 11.4x | 20.4x | 13.2x | 7.7x | 7.2x | ||
| Price / LTM Sales | 6.6x | 4.3x | 5.7x | 3.9x | 2.2x | 1.5x | ||
| LTM P/E Ratio | 19.2x | 17.7x | 25.8x | 27.8x | 17.3x | 10.6x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | 17.3x | 19.2x | 27.8x | |||||
| Historical LTM P/E Ratio | 12.9x | 15.9x | 45.9x | |||||
| Selected P/E Multiple | 14.6x | 15.4x | 16.1x | |||||
| (x) LTM Net Income | 3,289 | 3,289 | 3,289 | |||||
| (=) Equity Value | 47,973 | 50,498 | 53,023 | |||||
| (/) Shares Outstanding | 991.2 | 991.2 | 991.2 | |||||
| Implied Value Range | 48.40 | 50.94 | 53.49 | |||||
| FX Rate: DKK/DKK | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 48.40 | 50.94 | 53.49 | 36.44 | ||||
| Upside / (Downside) | 32.8% | 39.8% | 46.8% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | NOVO B | NOVN | ORNAV | AZN | PFE | HLUN B | |
| Value of Common Equity | 2,000,459 | 229,458 | 8,962 | 220,109 | 136,492 | 36,120 | |
| (/) Shares Outstanding | 4,439.1 | 1,959.3 | 140.7 | 1,550.7 | 5,685.4 | 991.2 | |
| Implied Stock Price | 450.65 | 117.12 | 63.70 | 141.95 | 24.01 | 36.44 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.23 | 1.00 | 0.10 | 1.16 | 1.00 | |
| Implied Stock Price (Trading Cur) | 450.65 | 95.08 | 63.70 | 1,358.00 | 20.69 | 36.44 | |
| Trading Currency | DKK | CHF | EUR | SEK | EUR | DKK | |
| FX Rate to Reporting Currency | 1.00 | 1.23 | 1.00 | 0.10 | 1.16 | 1.00 | |